Free Trial
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2023 Earnings Report

MAIA Biotechnology logo
$1.55 -0.02 (-1.27%)
Closing price 09/19/2025 04:10 PM Eastern
Extended Trading
$1.54 -0.01 (-0.32%)
As of 09/19/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MAIA Biotechnology EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 6, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Monday, November 10, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MAIA Biotechnology Earnings Headlines

Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary people pull consistent profits from crypto — not through luck or timing, but through a systematic approach with a documented 93% win rate.tc pixel
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat